Adding the VEGF inhibitor ramucirumab (Cyramza) to the EGFR inhibitor osimertinib (Tagrisso) slowed progression of untreated ...

Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncologic, ...

Indeed, additional promising drugs with multitarget activity (including ... Alternative RTK pathways that are activated following EGFR inhibition is another area for investigation.

The partners are studying a drug designed to target EGFR exon 19 or exon 21 mutations with a co-occurring C797S mutation.

Lazcluze demonstrated significant CNS activity, regardless of T790M status, in treating intracranial and leptomeningeal ...

The firm is focusing its resources on developing its lead candidate, the EGFR inhibitor BDTX-1535, which is undergoing testing in EGFR-mutated NSCLC.

Results showed treatment with osimertinib reduced the risk of disease progression or death by 84% compared with placebo.

US FDA approves AstraZeneca’s Tagrisso for patients with unresectable, stage III EGFR-mutated lung cancer: Cambridge, UK Friday, September 27, 2024, 11:00 Hrs [IST] AstraZenecas ...

“The development of drugs for indications related to both ... results from the combination of our two novel (cMET and EGFR) inhibitors in NSCLC patients with EGFR mutation-positive, MET ...

Patritumab deruxtecan is a specifically engineered potential first-in-class HER3 directed DXd antibody drug ... with EGFR-mutated non-small cell lung cancer with prior tyrosine kinase inhibitor ...

NKT2152 makes strides in RCC, the amivantamab/chemotherapy combination receives approval for EGFR-mutant NSCLC, and experts discuss the future of AML. We also highlight the approval of the 420-mg dose ...

Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced the U.S. Food and Drug ...